Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Free Dating
Ñompany Maksim-LLC. Ýëåêòðîïðèâîäû. Made and sell.
Popular Articles

Social Care Workforce Not Ready To Deliver Dementia Care - MPs
A report published revealed the social care workforce is unfit to deliver quality care for people with dementia.
new payday loan lenders
New Treatment Approach Gives Patients With Incurable Lung Cancer More Time Without Disease Progression Compared To Placebo
Results from a Phase III study presented at the American Society for Clinical Oncology (ASCO) Annual Meeting in Orlando, Florida today show that patients with advanced non-small cell lung cancer (NSCLC) who received erlotinib (Tarceva®) as first-line maintenance treatment benefited from a significant (29%) improvement in the time they lived without the disease advancing, compared with those who received placebo1. Patients in the global multicentre SATURN trial, which included patients from the UK, received maintenance treatment with erlotinib if their cancer had not progressed on initial chemotherapy. The data showed a significant improvement in the length of time patients lived without their disease getting worse, and without the need for further chemotherapy. 1 The improvement was seen in both of the main types of NSCLC (squamous cell as well as non-squamous cell) and these results form the basis of a submission for regulatory approval of erlotinib to be used in the first-line maintenance setting. 1 Erlotinib is not currently licensed for first line maintenance treatment in NSCLC lung cancer in the UK.
News of the day
ACCP Position Paper On Genetic Tests Advertised Directly To The Consumer
Genetic testing services have recently begun to be advertised directly to the patient, and the results of the consumers" response can affect public health, as well as the future adoption of pharmacogenetic/genomic testing, according to a position paper from the American College of Clinical Pharmacology (ACCP) to be published in the August 2009 issue of the Journal of Clinical Pharmacology. The journal is published on behalf of the ACCP by SAGE.
Public Health

New Drug Combination Offers Novel Treatment Strategy For Non-Hodgkin's Lymphoma

Patients diagnosed with non-Hodgkin"s lymphoma who become resistant to standard therapies may have a new treatment option. Scientists in the Lymphoma Translational Research Laboratory at Roswell Park Cancer Institute analyzed the mechanisms to overcome treatment resistance, including a new drug combination. Francisco J. Hernandez-Ilizaliturri, MD , Departments of Medicine and Immunology, Roswell Park Cancer Institute (RPCI), will present the findings at the American Society of Clinical Oncology (ASCO) 2009 annual meeting, May 29 - June 2, in Orlando, FL. "Strategies to Overcoming Rituximab-chemotherapy Resistance by Targeting the Autophagy Pathway Using Bortezomib in Combination with the Bcl-2 Inhibitor Obatoclax in non-Hodgkin"s Lymphomas (NHL)" Monday, June 1 - 5 pm EST Level 4, Valencia Room, W415A The Roswell Park investigators evaluated the biological effects of combining two drugs that target molecular pathways that play an important role in acquired resistance to standard therapies of rituximab and chemotherapy in non-Hodgkin"s lymphoma laboratory models. Obatoclax is an investigational drug designed to kill cancer cells by blocking a protein that usually prevents cell death. Bortezomib, the first approved cancer drug in a new class of medicines called proteasome inhibitors, disrupts the growth and survival of cancer cells. Scientists found that Obatoclax and Bortezomib are highly active against several lymphoma cell lines and tumor cells derived from patients with untreated or highly refractory lymphomas. When used in combination, the drugs demonstrated synergistic action. "This research contributes to the scientific understanding of the mechanisms responsible for rituximab resistance, which will ultimately result in the development of novel therapies and better outcomes for patients," said Dr. Hernandez-Ilizaliturri. "Our laboratory finding strongly suggests that Obatoclax and Bortezomib are an effective drug combination that has potential as a new treatment option for patients diagnosed with aggressive non-Hodgkin"s lymphoma and merits further investigation." The incidence of NHL has been steadily increasing over the past two decades and is now considered the second most rapidly increasing cause of cancer-related death in the United States. In 2009, approximately 65,980 new cases of NHL will be diagnosed and 19,500 patients will die from the disease. Roswell Park Cancer Institute


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009